Notably, early clinical data indicate ABBV-155 is safe in humans with a maximum tolerated dose (MTD) not reached and, unlike previous inhibitors of BCL-XL, does not impact platelets to a significant degree (i.e., no thrombocytopenia)46. This evidence concerns the gene BCL2L1 and Thrombocytopenia.